MRNA raises price target to $120 from $67 after Phase 3 data
MRNA’s MRK-partnered intismeran autogene plus Keytruda therapy price target is lifted to $120 from $67 following a reported positive late-stage Ph3 result in completely resected Stage IIB-IV melanoma.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.